S&P 500 7,387.05 â–ŧ 197.26 (-2.60%) DOW 50,877.30 â–ŧ 684.63 (-1.33%) NASDAQ 25,726.49 â–ŧ 1,104.47 (-4.12%) US Markets Closed â€ĸ 02:36 PM ET

APM

Aptorum Group Limited

Price Chart
Latest Quote

$1.09

+0.00 (+0.00%)
Current Price
Previous Close $1.09
Open $1.06
Day High $1.15
Day Low $1.01
Volume 501,659
Fetched: 2026-06-05T08:00:47
Stock Information
Shares Outstanding 6.35M
Total Debt $3.44M
Cash Equivalents $3.45M
Net Income $-1.36M
Sector Healthcare
Industry Biotechnology
Market Cap $8.23M
EPS (TTM) $-0.19
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$-1.16M
Income$-1.36M
Book/sh$2.84
Cash/sh$0.54
Employees1
Financial Ratios
Quick Ratio0.75
Current Ratio0.78
Debt/Eq25.05
Returns & Margins
ROA-6.52%
ROE-10.79%
Ownership
Insider Ownership16.41%
Institutional Ownership2.47%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-1.42
P/B0.36
Analyst Data
Recommendationnone
Technical Indicators
SMA20$0.90
SMA50$0.89
SMA200$1.24
RSI64.10
ATR0.1321
Shares Float5.36M
Short Float0.23%
Short Ratio0.65
Volatility0.12
Rel Volume7.19
Performance History
Week-1.94%
Month+18.82%
Quarter+26.25%
6 Months-26.28%
YTD-5.61%
Year-15.13%
3 Years-67.83%
5 Years-96.39%
10 Years-99.30%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-05 $1.01 1,159,100
2026-06-04 $1.09 554,200
2026-06-03 $1.09 113,600
2026-06-02 $0.98 146,400
2026-06-01 $1.07 543,900
2026-05-29 $1.03 451,000
2026-05-28 $0.84 16,300
2026-05-27 $0.85 4,400
2026-05-26 $0.85 20,500
2026-05-22 $0.85 5,300
2026-05-21 $0.83 9,400
2026-05-20 $0.81 15,400
2026-05-19 $0.84 23,000
2026-05-18 $0.86 44,000
2026-05-15 $0.82 9,300
2026-05-14 $0.85 24,100
2026-05-13 $0.80 24,600
2026-05-12 $0.82 9,400
2026-05-11 $0.83 37,900
2026-05-08 $0.84 10,700
2026-05-07 $0.84 17,100
2026-05-06 $0.85 32,400
About Aptorum Group Limited

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Reconciled Cost Of Revenue $0 $0 $420,812 $1,215,824
Cost Of Revenue $0 $0 $420,812 $1,215,824
Total Revenue $0 $0 $431,378 $1,295,889
Operating Revenue $0 $0 $431,378 $1,295,889
Expenses
Total Expenses $1,817,528 $3,002,298 $11,032,614 $18,469,503
Rent Expense Supplemental $126,336 $97,253 $213,701 $265,558
Other Income Expense $536,811 $-1,008,515 $6,381,406 $5,501,924
Net Non Operating Interest Income Expense $-95,713 $-146,924 $-121,145 $146,588
Total Other Finance Cost $95,713 $146,924 $121,145 $-146,588
Operating Expense $1,817,528 $3,002,298 $10,611,802 $17,253,679
Other Operating Expenses $-170,756 $-655,852 $944,675 $-74,461
General And Administrative Expense $1,635,405 $1,459,509 $4,366,017 $7,866,965
Other Non Operating Income Expenses - $564 $36,784 $48,007
Selling And Marketing Expense - $0 $48,982 $98,082
Interest Expense - - - -
Interest Expense Non Operating - - - -
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-1,363,270 $-4,267,806 $-2,824,647 $-9,799,560
Net Interest Income $-95,713 $-146,924 $-121,145 $146,588
Normalized Income $-1,900,081 $-3,258,727 $-9,169,269 $-15,253,477
Net Income From Continuing And Discontinued Operation $-1,363,270 $-4,267,806 $-2,824,647 $-9,799,560
Net Income Common Stockholders $-1,363,270 $-4,267,806 $-2,824,647 $-9,799,560
Net Income $-1,363,270 $-4,267,806 $-2,824,647 $-9,799,560
Net Income Including Noncontrolling Interests $-1,376,430 $-4,157,737 $-4,340,975 $-11,525,102
Net Income Continuous Operations $-1,376,430 $-4,157,737 $-4,340,975 $-11,525,102
Pretax Income $-1,376,430 $-4,157,737 $-4,340,975 $-11,525,102
Special Income Charges $0 $-1,009,079 $-77,200 $-520,821
Operating Income $-1,817,528 $-3,002,298 $-10,601,236 $-17,173,614
Depreciation Amortization Depletion Income Statement $0 $3,480 $53,799 $143,498
Depreciation And Amortization In Income Statement $0 $3,480 $53,799 $143,498
Gross Profit $0 $0 $10,566 $80,065
Interest Income - - - $146,588
Interest Income Non Operating - - - $146,588
Per Share
Diluted EPS - - $-0.62 $-2.75
Basic EPS - - $-0.62 $-2.75
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-2,354,339 $-1,687,653 $-15,568,259 $-21,070,990
Total Unusual Items $536,811 $-1,009,079 $6,344,622 $5,453,917
Total Unusual Items Excluding Goodwill $536,811 $-1,009,079 $6,344,622 $5,453,917
Reconciled Depreciation $0 $305,566 $1,377,599 $1,556,541
EBITDA (Bullshit earnings) $-1,817,528 $-2,696,732 $-9,223,637 $-15,617,073
EBIT $-1,817,528 $-3,002,298 $-10,601,236 $-17,173,614
Diluted NI Availto Com Stockholders $-1,363,270 $-4,267,806 $-2,824,647 $-9,799,560
Minority Interests $13,160 $-110,069 $1,516,328 $1,725,542
Gain On Sale Of Business $0 $703 $0 $0
Write Off $0 $1,009,782 $77,200 $520,821
Gain On Sale Of Security $536,811 - $6,421,822 $5,974,738
Research And Development $352,879 $2,195,161 $5,198,329 $9,219,595
Selling General And Administration $1,635,405 $1,459,509 $4,414,999 $7,965,047
Other Gand A $1,285,780 $818,292 $2,784,133 $3,261,365
Insurance And Claims $215,128 $335,616 $474,746 $546,675
Rent And Landing Fees $126,336 $97,253 $213,701 $265,558
Salaries And Wages $8,161 $208,348 $893,437 $3,793,367
Diluted Average Shares - - $4,521,133 $3,569,484
Basic Average Shares - - $4,521,133 $3,569,484
Gain On Sale Of Ppe - - $0 $0
Otherunder Preferred Stock Dividend - - - $0
Fetched: 2026-06-05
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $23,162,160 $21,134,514 $24,698,889 $14,959,389
Total Assets $18,691,370 $16,130,223 $20,640,091 $20,867,371
Total Non Current Assets $15,098,846 $15,170,669 $18,163,999 $13,799,569
Non Current Prepaid Assets $0 $71,823 $71,823 $127,303
Goodwill And Other Intangible Assets $0 $0 $147,347 $752,705
Current Assets $3,592,524 $959,554 $2,476,092 $7,067,802
Prepaid Assets $139,633 $80,771 $399,796 $539,256
Receivables $0 $4,545 $70,945 $1,385,463
Cash Cash Equivalents And Short Term Investments $3,452,891 $874,238 $2,005,351 $1,985,026
Cash And Cash Equivalents $3,452,891 $874,238 $2,005,351 $1,882,545
Cash Financial $3,452,891 $874,238 $2,005,351 $1,882,545
Other Receivables - $4,545 $22,275 $205,404
Accounts Receivable - $0 $47,709 $174,426
Other Intangible Assets - - $147,347 $752,705
Restricted Cash - - $0 $3,130,335
Inventory - - $0 $27,722
Loans Receivable - - $0 $875,956
Hedging Assets Current - - - -
Debt
Total Debt $3,442,928 $3,354,907 $3,283,217 $6,854,566
Long Term Debt And Capital Lease Obligation $0 $14,182 $3,157,985 $530,784
Current Debt And Capital Lease Obligation $3,442,928 $3,340,725 $125,232 $6,323,782
Current Debt $3,418,500 $3,238,500 - $6,013,234
Other Current Borrowings $3,418,500 $3,238,500 - $3,013,234
Net Debt - $2,364,262 $1,053,149 $4,630,689
Long Term Debt - - $3,058,500 $500,000
Liabilities
Total Liabilities Net Minority Interest $4,899,823 $4,353,162 $5,256,738 $13,034,066
Total Non Current Liabilities Net Minority Interest $306,000 $14,182 $3,157,985 $530,784
Derivative Product Liabilities $306,000 $0 - -
Current Liabilities $4,593,823 $4,338,980 $2,098,753 $12,503,282
Payables And Accrued Expenses $1,150,895 $998,255 $1,973,521 $6,179,500
Payables $1,094,616 $984,880 $1,957,608 $6,059,665
Other Payable $1,015,436 $905,236 $1,878,428 $6,046,972
Equity
Common Stock Equity $23,162,160 $21,134,514 $24,846,236 $15,712,094
Total Equity Gross Minority Interest $13,791,547 $11,777,061 $15,383,353 $7,833,305
Stockholders Equity $23,162,160 $21,134,514 $24,846,236 $15,712,094
Other Equity Interest $47,000 - - -
Gains Losses Not Affecting Retained Earnings $-92,310 $89,162 $-10,623 $33,807
Other Equity Adjustments $-92,310 $89,162 $-10,623 $33,807
Retained Earnings $-73,792,798 $-72,429,528 $-68,161,722 $-65,337,075
Other
Ordinary Shares Number $8,143,757 $5,608,757 $5,181,697 $3,570,729
Share Issued $8,143,757 $5,608,757 $5,181,697 $3,570,729
Tangible Book Value $23,162,160 $21,134,514 $24,698,889 $14,959,389
Invested Capital $26,580,660 $24,373,014 $27,904,736 $22,225,328
Working Capital $-1,001,299 $-3,379,426 $377,339 $-5,435,480
Capital Lease Obligations $24,428 $116,407 $224,717 $341,332
Total Capitalization $23,162,160 $21,134,514 $27,904,736 $16,212,094
Minority Interest $-9,370,613 $-9,357,453 $-9,462,883 $-7,878,789
Additional Paid In Capital $97,000,188 $93,474,825 $93,018,528 $45,308,080
Capital Stock $80 $55 $53 $35,707,282
Common Stock $80 $55 $53 $35,707,282
Long Term Capital Lease Obligation $0 $14,182 $99,485 $30,784
Current Capital Lease Obligation $24,428 $102,225 $125,232 $310,548
Current Accrued Expenses $56,279 $13,375 $15,913 $119,835
Dueto Related Parties Current $79,180 $79,644 $79,180 $12,693
Investments And Advances $15,098,846 $15,098,846 $16,098,846 $9,744,958
Net PPE $0 $0 $1,845,983 $3,174,603
Accumulated Depreciation $-4,784,728 $-4,784,728 $-3,687,336 $-4,570,455
Gross PPE $4,784,728 $4,784,728 $5,533,319 $7,745,058
Leases $108,187 $108,187 $543,975 $543,975
Other Properties $4,335,722 $4,335,722 $4,336,764 $6,229,072
Machinery Furniture Equipment $340,819 $340,819 $470,523 $622,467
Properties $0 $0 $0 $0
Buildings And Improvements - $0 $182,057 $347,000
Duefrom Related Parties Current - $0 $961 $129,677
Line Of Credit - - $0 $3,000,000
Construction In Progress - - $0 $2,544
Other Short Term Investments - - $0 $102,481
Fetched: 2026-06-05
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-1,836,546 $-1,189,734 $-7,727,379 $-12,505,881
Operating Activities
Operating Cash Flow $-1,836,546 $-1,189,734 $-7,724,364 $-12,318,965
Cash Flow From Continuing Operating Activities $-1,836,546 $-1,189,734 $-7,724,364 $-12,318,965
Operating Gains Losses $-536,811 $-59,324 $120,118 $339,323
Investing Activities
Investing Cash Flow $0 $58,621 $624,767 $2,444,896
Cash Flow From Continuing Investing Activities $0 $58,621 $624,767 $2,444,896
Capital Expenditure - - $-3,015 $-186,916
Net Other Investing Changes - - $519,182 $2,631,812
Financing Activities
Issuance Of Capital Stock $5,070,000 $0 $1,575,562 $5,360
Financing Cash Flow $4,415,199 $0 $4,092,068 $6,625,462
Cash Flow From Continuing Financing Activities $4,415,199 $0 $4,092,068 $6,625,462
Net Other Financing Charges $-654,801 - - -
Net Common Stock Issuance $5,070,000 $0 $1,575,562 $5,360
Common Stock Issuance $5,070,000 $0 $1,575,562 $5,360
Other
Repayment Of Debt $0 $0 $-3,000,000 $-49,358
Issuance Of Debt $0 $0 $5,500,000 $6,500,000
Interest Paid Supplemental Data $0 $0 $94,108 $64,744
End Cash Position $3,452,891 $874,238 $2,005,351 $5,012,880
Beginning Cash Position $874,238 $2,005,351 $5,012,880 $8,261,487
Changes In Cash $2,578,653 $-1,131,113 $-3,007,529 $-3,248,607
Proceeds From Stock Option Exercised $0 $0 $16,506 $169,460
Net Issuance Payments Of Debt $0 $0 $2,500,000 $6,450,642
Net Long Term Debt Issuance $0 $0 $2,500,000 $6,450,642
Long Term Debt Payments $0 $0 $-3,000,000 $-49,358
Long Term Debt Issuance $0 $0 $5,500,000 $6,500,000
Net Investment Purchase And Sale $0 $0 $93,215 $0
Sale Of Investment $0 $0 $93,215 $0
Net PPE Purchase And Sale $0 $58,621 $12,370 $-186,916
Sale Of PPE $0 $58,621 $15,385 $0
Purchase Of PPE $0 $0 $-3,015 $-186,916
Change In Working Capital $-103,305 $-209,677 $461,592 $1,397,913
Change In Other Current Liabilities $-91,979 $-120,824 $-389,365 $-369,505
Change In Payables And Accrued Expense $-28,832 $-422,241 $390,111 $1,911,946
Change In Payable $-28,832 $-422,241 $390,111 $1,911,946
Change In Account Payable $-28,368 $-422,705 $398,635 $1,918,751
Change In Prepaid Assets $0 $0 $29,106 $19,328
Change In Inventory $0 $0 $14,516 $8,053
Change In Receivables $17,506 $333,388 $417,224 $-171,909
Changes In Account Receivables $0 $41,349 $126,717 $-95,704
Other Non Cash Items $180,000 $180,000 $-1,600,962 $-146,588
Stock Based Compensation $0 $0 $1,265,189 $1,646,999
Unrealized Gain Loss On Investment Securities $0 $0 $-6,431,088 $-6,108,872
Provisionand Write Offof Assets $0 $0 $521,007 $0
Asset Impairment Charge $0 $2,751,438 $903,156 $520,821
Depreciation Amortization Depletion $0 $305,566 $1,377,599 $1,556,541
Depreciation And Amortization $0 $305,566 $1,377,599 $1,556,541
Depreciation $0 $305,566 $1,377,599 $1,556,541
Gain Loss On Investment Securities $-536,811 - $9,266 $134,134
Gain Loss On Sale Of Business $0 $-703 $0 $0
Net Income From Continuing Operations $-1,376,430 $-4,157,737 $-4,340,975 $-11,525,102
Income Tax Paid Supplemental Data - $0 $0 $0
Net Short Term Debt Issuance - - $0 $6,000,000
Short Term Debt Payments - - $-3,000,000 $0
Short Term Debt Issuance - - $3,000,000 $6,000,000
Net Business Purchase And Sale - - $0 $0
Purchase Of Business - - $0 $0
Net Intangibles Purchase And Sale - - $0 $0
Purchase Of Intangibles - - $0 $0
Amortization Cash Flow - - $84,020 $114,553
Amortization Of Intangibles - - $84,020 $114,553
Gain Loss On Sale Of PPE - - $110,852 $205,189
Fetched: 2026-06-05